 | • レポートコード：B-MOR-08219 • 出版社/出版日：Mordor Intelligence / 2018年5月1日 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、ヘアリーセル白血病の世界市場について調べ、ヘアリーセル白血病の世界規模、市場動向、市場環境、治療法別（化学療法、クラドリビン、ペントスタチン、その他）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・ヘアリーセル白血病の世界市場インサイト ・ヘアリーセル白血病の世界市場環境 ・ヘアリーセル白血病の世界市場動向 ・ヘアリーセル白血病の世界市場規模 ・ヘアリーセル白血病の世界市場規模：治療法別（化学療法、クラドリビン、ペントスタチン、その他） ・ヘアリーセル白血病の世界市場：地域別市場規模・分析 ・ヘアリーセル白血病の北米市場規模・予測 ・ヘアリーセル白血病のアメリカ市場規模・予測 ・ヘアリーセル白血病のヨーロッパ市場規模・予測 ・ヘアリーセル白血病のアジア市場規模・予測 ・ヘアリーセル白血病の日本市場規模・予測 ・ヘアリーセル白血病の中国市場規模・予測 ・ヘアリーセル白血病のインド市場規模・予測 ・ヘアリーセル白血病の韓国市場規模・予測 ・関連企業情報・競争状況 |
The hairy cell leukaemia market is expected to register a CAGR of 5% during the forecast period 2018 to 2023. Hairy cell leukaemia is a type of blood cancer associated with accumulation of abnormal lymphocytes.
Increase in Diagnosis Rates
Hairy cell leukaemia is a very rare type of cancer, which accounts for approximately 2% of leukaemia’s. Hairy cell leukaemia is characterized by the uncontrolled accumulation of lymphocytes by bone marrow, overproducing them. Early diagnosis can help the patients live longer. In recent years, there are advanced diagnostic tests to detect the hairy cell leukaemia. First and foremost diagnostic test is a complete blood profile which clearly indicates the total number of lymphocytes, which indicates the disease. Physicians can easily diagnose, if there is an enlarged spleen, by physical examination. One important confirmation test is presence of hairy cells in the blood in the lab tests. Finally, most of the patients require bone marrow biopsy for confirmation. Most of the patients who receive treatment can be disease-free for at least 10 years. Diagnosis rate of hairy cell leukaemia is increased during last two-three decades, which drives the market. The other factors which drives the market is growing geriatric population
Lack of Awareness of Symptoms Due to Insignificant Research Studies
Hairy cell leukaemia is very infrequent type of leukaemia, which is rarely known to the people all over the world. There is no proper data available on incidence or prevalence of hairy cell leukaemia, which implies an insufficient research documents. This disease can be treated if diagnosed in early stages, but due to lack of awareness of the symptoms of hairy cell leukaemia among people limits the diagnosis of the disease, which is a major factor restricting the growth of the market. The other factors, such as limited health services in rural hospitals, is the major restraint for the global hairy cell leukaemia market.
North America Lead the Market
The hairy cell leukaemia market holds the largest market share in North America Region for the year 2017 due to the presence of high incidence rate, increase in ageing population and advancements in the treatment of hairy cell leukaemia which is followed by Europe
Major Players: ABBVIE, ASTELLAS PHARMA, ASTRAZENECA, BIOGENOMICS LIMITED, F. HOFFMANN-LA ROCHE AG, INCYTE CORP., JUNO THERAPEUTICS, MEDIMMUNE, AND NOVARTIS, among others.
Reasons to Purchase this Report
• Current and future hairy cell leukaemia market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support along with the Market Estimate sheet (in excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increase in Diagnosis Rates
6.1.2 Growing Geriatric Population
6.2 Market Restraints
6.2.1 Lack of Awareness of the Symptoms Due to Insignificant Research Studies
6.2.2 Limited Health Services in Rural Hospitals
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Therapy
7.1.1 Chemotherapy
7.1.1.1 Cladribine
7.1.1.2 Pentostatin
7.1.1.3 Others
7.2 Segmentation – by Geography
7.2.1 North America
7.2.1.1 United States
7.2.1.2 Canada
7.2.1.3 Mexico
7.2.2 Europe
7.2.2.1 France
7.2.2.2 Germany
7.2.2.3 United Kingdom
7.2.2.4 Italy
7.2.2.5 Spain
7.2.2.6 Rest of Europe
7.2.3 Asia-Pacific
7.2.3.1 China
7.2.3.2 Japan
7.2.3.3 India
7.2.3.4 Australia
7.2.3.5 New Zealand
7.2.3.6 South Korea
7.2.3.7 Rest of Asia-Pacific
7.2.4 Middle East & Africa
7.2.4.1 GCC
7.2.4.2 South Africa
7.2.4.3 Rest of Middle East & Africa
7.2.5 South America
7.2.5.1 Brazil
7.2.5.2 Argentina
7.2.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.1 AbbVie
9.2 Astellas Pharma
9.3 AstraZeneca
9.4 Biogenomics Limited
9.5 F. Hoffmann-La Roche AG
9.6 Incyte Corp.
9.7 Juno Therapeutics
9.8 MedImmune
9.9 Novartis
9.10 Others
10. Future of the Market